Detalhe da pesquisa
1.
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
J Antimicrob Chemother
; 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38758191
2.
Efficacy and safety of raltegravir plus lamivudine maintenance therapy.
J Antimicrob Chemother
; 79(2): 255-261, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039097
3.
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
J Antimicrob Chemother
; 78(8): 1955-1962, 2023 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311224
4.
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
J Antimicrob Chemother
; 78(12): 2961-2967, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875023
5.
Sex-based epidemiological and immunovirological characteristics of people living with HIV in current follow-up at a tertiary hospital: a comparative retrospective study, Catalonia, Spain, 1982 to 2020.
Euro Surveill
; 28(10)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892474
6.
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
J Antimicrob Chemother
; 77(7): 1974-1979, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512339
7.
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
J Antimicrob Chemother
; 77(4): 1133-1139, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35040990
8.
Chemsex Practices in PrEP: Beyond Addiction and Risk Toward a Healthy Sex Life-Baseline Experiences from a Hospital-Based PrEP Program in Barcelona, Spain.
AIDS Behav
; 26(12): 4055-4062, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35732910
9.
Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4+ T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy.
Int J Mol Sci
; 23(4)2022 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216318
10.
Factors associated with the use and composition of two-drug regimens in a large single-centre HIV cohort.
J Antimicrob Chemother
; 76(11): 2988-2992, 2021 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34293162
11.
Efficacy of Elbasvir/Grazoprevir in Early Chronic G1/G4 Hepatitis C infection in HIV/HCV co-infected patients with mild fibrosis.
Gastroenterol Hepatol
; 44(3): 191-197, 2021 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-33041087
12.
Quality of life in patients with hepatitis C. Importance of treatment. / Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento.
Gastroenterol Hepatol
; 42 Suppl 1: 20-25, 2019 Sep.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-32560769
13.
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Gastroenterol Hepatol
; 42(3): 164-170, 2019 Mar.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-30293914
14.
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
J Antimicrob Chemother
; 73(7): 1965-1971, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29608685
15.
Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.
Hepatology
; 66(2): 344-356, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28109003
16.
Tolerability of integrase inhibitors in a real-life setting.
J Antimicrob Chemother
; 72(6): 1752-1759, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28333231
17.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467560
18.
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
J Antimicrob Chemother
; 71(7): 1975-81, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27021341
19.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
J Antimicrob Chemother
; 71(7): 1987-93, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26994089
20.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
J Antimicrob Chemother
; 71(7): 1982-6, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26994091